Table 3. Adjusted odds ratios (ORs) with associated 95% confidence interval (CI) for insulin resistance, metabolic syndrome and NAFLD.
| Variables | Insulin resistance |
Metabolic syndrome |
NAFLD |
||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95%CI | P value | OR | 95%CI | P value | OR | 95%CI | P value | |
| Model 1 | |||||||||
| Hyperuricemia (yes v.s. no) | 1.567 | 1.245–1.974 | <0.001* | 1.890 | 1.486–2.404 | <0.001* | 2.370 | 1.864–3.012 | <0.001* |
| Serum uric acid† | 1.434 | 1.257–1.636 | <0.001* | 1.581 | 1.374–1.818 | <0.001* | 1.722 | 1.496–1.983 | <0.001* |
| Serum uric acid ‡ | |||||||||
| (Quartile 2 vs. Quartile 1) | 1.393 | 1.027–1.889 | 0.033* | 1.447 | 1.064–1.968 | 0.018* | 1.396 | 1.029–1.893 | 0.032* |
| (Quartile 3 vs. Quartile 1) | 2.012 | 1.456–2.780 | <0.001* | 2.256 | 1.623–3.135 | <0.001* | 2.552 | 1.844–3.533 | <0.001* |
| (Quartile 4 vs. Quartile 1) | 2.363 | 1.658–3.367 | <0.001* | 2.685 | 1.864–3.866 | <0.001* | 3.524 | 2.445–5.079 | <0.001* |
| Trend test | <0.001* | <0.001* | <0.001* | ||||||
| Model 2 | |||||||||
| Hyperuricemia (yes v.s. no) | 1.565 | 1.242–1.973 | <0.001* | 1.884 | 1.480–2.396 | <0.001* | 2.423 | 1.903–3.086 | <0.001* |
| Serum uric acid† | 1.436 | 1.258–1.639 | <0.001* | 1.582 | 1.375–1.821 | <0.001* | 1.762 | 1.528–2.031 | <0.001* |
| Serum uric acid‡ | |||||||||
| (Quartile 2 vs. Quartile 1) | 1.390 | 1.024–1.888 | 0.035* | 1.441 | 1.059–1.962 | 0.020* | 1.440 | 1.059–1.958 | 0.020* |
| (Quartile 3 vs. Quartile 1) | 2.011 | 1.453–2.781 | <0.001* | 2.247 | 1.616–3.126 | <0.001* | 2.648 | 1.908–3.676 | <0.001* |
| (Quartile 4 vs. Quartile 1) | 2.359 | 1.652–3.367 | <0.001* | 2.678 | 1.856–3.862 | <0.001* | 3.715 | 2.566–5.378 | <0.001* |
| Trend test | <0.001* | <0.001* | <0.001* | ||||||
| Model 3 | |||||||||
| Hyperuricemia (yes v.s. no) | 1.268 | 0.987–1.630 | 0.063 | 1.533 | 1.186–1.982 | 0.001* | 1.992 | 1.516–2.618 | <0.001* |
| Serum uric acid† | 1.231 | 1.067–1.420 | 0.004* | 1.345 | 1.160–1.560 | <0.001* | 1.762 | 1.528–2.031 | <0.001* |
| Serum uric acid ‡ | |||||||||
| (Quartile 2 vs. Quartile 1) | 1.176 | 0.846–1.634 | 0.335 | 1.163 | 0.839–1.613 | 0.365 | 1.105 | 0.779–1.567 | 0.575 |
| (Quartile 3 vs. Quartile 1) | 1.545 | 1.091–2.188 | 0.014* | 1.652 | 1.165–2.342 | 0.005* | 1.908 | 1.318–2.762 | 0.001* |
| (Quartile 4 vs. Quartile 1) | 1.678 | 1.142–2.466 | 0.008* | 1.748 | 1.180–2.588 | 0.005* | 2.475 | 1.622–3.777 | <0.001* |
| Trend test | 0.004* | 0.001* | <0.001* | ||||||
*p < 0.05.
†OR and 95%CI was impressed by per SD increase of serum uric acid.
‡OR and 95%CI was impressed by the first quartile of serum uric acid as the reference.
Model 1: was adjusted for sex and age. Model 2: was further adjusted for educational level, ever smoking, ever drinking and regular physical exercise. Model 3: For insulin resistance, model 3 was further adjusted for waist, systolic blood pressure, triglyceride, HDL-cholesterol; For metabolic syndrome, model 3 was further adjusted for fasting insulin; For NAFLD, model 3 was further adjusted for waist, systolic blood pressure, triglyceride, HDL-cholesterol, fasting plasma glucose and fasting insulin.